Finland· FI-REL-REL6187
Mucomyst
A acetylcysteine product, registered in Finland by Tika Läkemedel Ab. The same ATC class is registered in 15 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Acetylcysteine is registered in 15 of 19 countries.
Countries holding a registration under ATC R05CB01 (acetylcysteine), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Acetylcysteine · ATC R05CB01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of acetylcysteine costs, country by country.
Normalised to the WHO defined daily dose (0.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Acetylcysteine · price per daily dose (0.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$0.47
The record
At a glance
Fimea (Finland)- Manufacturer
- Tika Läkemedel Ab
- Country
- Finland (FI)
- ATC code
- R05CB01
- ATC class
- Acetylcysteine
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
314 interactions on record for acetylcysteine.
Graded by severity as the source publishes them — 5 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acetylcysteine · interactions on record
314 records
- 5 moderate
- 2 minor
- 307 info
Most severe, free to view
- Insulin (human)A10AB01moderate
- Insulin (human)A10AC01moderate
- Insulin (human)A10AD01moderate
- Insulin (human)A10AE01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R05CB01
Acetylcysteine, as other registers publish it.
- United KingdomA-CYS 200mg granules sachetsEnnogen Healthcare International Ltd
- United KingdomA-CYS 600mg capsulesEnnogen Healthcare International Ltd
- United KingdomA-CYS 600mg effervescent tabletsEnnogen Healthcare Ltd
- United KingdomA-CYS 600mg effervescent tabletsEnnogen Healthcare International Ltd
- United KingdomA-CYS 600mg tabletsEnnogen Healthcare International Ltd
- United KingdomAbNAC 600mg capsulesMaN Pharma Ltd
- United KingdomAbNAC 600mg tabletsMaN Pharma Ltd
- GermanyAccHexal Ag
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e5087183-e9c9-46f9-a6bf-bb643a34bca5 GET /v1/drugs/e5087183-e9c9-46f9-a6bf-bb643a34bca5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.5",
"form": "poretabletti",
"route": null,
"ddd_unit": "g",
"strength": "200 mg",
"atc_label": "asetyylikysteiini",
"ma_number": "8860",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL6187",
"authorised_at": "1984-10-10"
}See everything about acetylcysteine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.